Hypertension and kidney disease: What do the data really show?

Current Hypertension Reports

Volumn 14, Issue 5, 2012, Pages 462-467

  Cohen, Debbie L ^a   Townsend, Raymond R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AASK; African American Study of Kidney Disease and Hypertension; Blood pressure (BP) goal; Cardiovascular disease; Chronic kidney disease; CKD; CVD; Diabetes; End stage renal disease; ESRD; Hypertension; MDRD; Modification of diet in renal disease; Proteinuria; Ramipril efficacy in nephropathy 2; REIN 2

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FELODIPINE; FUROSEMIDE; HYDRALAZINE; METOPROLOL; MINOXIDIL; PLACEBO; RAMIPRIL;

ADD ON THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; MEAN ARTERIAL PRESSURE; MORTALITY; NEPHROSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84870487037     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0285-4     Document Type: Review

References (23)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-47.
2. Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2010;55:441-51. This study describes the awareness, treatment, and control of hypertension in subjects from the chronic renal insufficiency cohort study..
3. Wright Jr. JT, Agodoa L, Contreras G, Greene T, Douglas JG, Lash J, et al. African American study of kidney disease and hypertension study group successful blood pressure control in the AfricanAmerican study of kidney disease and hypertension. Arch Intern Med. 2002;162:1636-43.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr. JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
5. Snyder JJ, Collins AJ. KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: national health and nutrition examination survey 1999-2004. Am J Nephrol. 2009;30:44-54.
6. CKD KGfBi. In press. The KDIGO guideline offers clinical practice guidelines for goal BP in CKD. 2012. http://www.kdigo.org/clinical-practice- guidelines/Hypertension.php. Accessed 16 Jul 2012.
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305.
8. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541-8. This Study Reviews The Effects Of Different BP Goals And Levels Of Proteinuria On CKD Outcomes. The Data Are Derived From The AASK MDRD And REIN-2 Studies.
9. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The modification of diet in renal disease study group. Hypertension. 1997;29:641-50.
10. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med. 1994;330:877.
11. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med. 1995;123:754-62.
12. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, et al. Cardiovascular outcomes in the African American study of kidney disease and hypertension (AASK) trial. Am J Kidney Dis. 2006;48:739-51.
13. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicenter, randomized controlled trial. Lancet. 2005;365:939-46.
14. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142:342-51.
15. Appel LJ, Wright Jr. JT, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918-29. This follow-up of the AASK study assessed standard versus low BP goals in Black patients and did not show any benefit on CKD outcomes in Black patients without baseline proteinuria..
16. Arguedas JA, Perez MI,Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009;CD004349.
17. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303:423-9. This epidemiological study from Canada assessed the role of BP and protienuria on CKD progression..
18. Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J. 2011;32:1493-9. This is a post-hoc analysis of two important CKD trials assessing the effects of BP and proteinuria on CKD progression..
19. Kramer BK, Schweda F. Ramipril in non-diabetic renal failure (REIN study). Ramipril efficiency in nephropathy study. Lancet. 1997;350:736-7.
20. Cushman WC, Evans GW, Byington RP, Goff Jr. DC, Grimm Jr. RH, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85. The ACCORD study assessed the effects of standard versus usual SBP goals on CV outcomes and CKD in subjects with Type 2 diabetes..
21. Peralta CA, Norris KC, Li S, Chang TI, Tamura MK, Jolly SE, et al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the kidney early evaluation program (KEEP). Arch Intern Med. 2012;172:41-7. This study is an observational study from the KEEP data assessing SBP, DBP, and PP and risk for progression to ESRD..
22. SPRINT. Systolic Blood Pressure Intervention Trial (SPRINT) (http://clinicaltrials.gov/ct2/show/NCT01206062). Accessed 29 May 2012.
23. HALT-PKD. http://clinicaltrials.gov/ct2/show/NCT00283686? term0halt+pkd&rank01. Accessed 29 May 2012.